MX2022011372A - Composiciones de zinc-y-pga y metodos para tratar el cancer. - Google Patents

Composiciones de zinc-y-pga y metodos para tratar el cancer.

Info

Publication number
MX2022011372A
MX2022011372A MX2022011372A MX2022011372A MX2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A
Authority
MX
Mexico
Prior art keywords
methods
tumors
compositions
zinc
treating cancer
Prior art date
Application number
MX2022011372A
Other languages
English (en)
Inventor
Jinhyuk Fred Chung
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Publication of MX2022011372A publication Critical patent/MX2022011372A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden una sal de zinc2+ y un vehículo de ácido ?-poliglutámico y, opcionalmente, un inhibidor de NF-?B como agente de sensibilización de tumor, y a métodos para usar tales composiciones para tratar tumores en pacientes. Los métodos incluyen administrar una forma de dosis líquida o una forma de dosis sólida de una cantidad terapéuticamente eficaz de una sal de Zn(II) y un vehículo de ácido ?-poliglutámico a un paciente que lo requiera. Se proveen métodos de tratamiento de un amplio espectro de tumores humanos que incluyen tumores con un fenotipo resistente a fármaco usando las composiciones divulgadas. Los tumores que responden a las composiciones farmacéuticas aquí divulgadas incluyen tumores neuroendocrinos (neuroblastoma), gástricos, uterinos y pulmonares.
MX2022011372A 2016-11-01 2019-04-30 Composiciones de zinc-y-pga y metodos para tratar el cancer. MX2022011372A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2022011372A true MX2022011372A (es) 2022-10-10

Family

ID=60327362

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005104A MX395613B (es) 2016-11-01 2017-10-31 COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
MX2022011372A MX2022011372A (es) 2016-11-01 2019-04-30 Composiciones de zinc-y-pga y metodos para tratar el cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019005104A MX395613B (es) 2016-11-01 2017-10-31 COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.

Country Status (10)

Country Link
US (2) US11944640B2 (es)
EP (1) EP3534914B1 (es)
JP (2) JP7083835B2 (es)
KR (1) KR102616690B1 (es)
CN (2) CN108014131B (es)
AU (2) AU2017354787B2 (es)
CA (1) CA3042383A1 (es)
MX (2) MX395613B (es)
SG (3) SG10201609131YA (es)
WO (1) WO2018084806A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
WO2019245458A1 (en) * 2018-06-22 2019-12-26 Xylonix Ip Holdings Pte. Ltd. Oncology treatments using zinc agents
KR102094182B1 (ko) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 아연 함유 수용성 폴리글루타믹산 복합체 조성물
US20220401573A1 (en) * 2019-12-27 2022-12-22 Wuhan Vast Conduct Science Foundation Co., Ltd. Composition and method for treatment of multiple sclerosis
JP2024510327A (ja) 2021-03-18 2024-03-06 ジロニックス・ピーティーイー．リミテッド 医薬ポリマーコンジュゲート

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (ja) 1989-06-28 1998-02-16 味の素株式会社 易吸収性ミネラル含有飲食物
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
DE69330595T2 (de) 1992-11-25 2002-05-23 Ajinomoto Co., Inc. Zubereitungen und Nahrungsmittel enthaltend Mineralien und Poly-gamma-Glutaminsäure
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ITMI950515A0 (it) 1995-03-16 1995-03-16 Valpharma Sa Formulazioni gastroresistenti contenenti zinco
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (ja) 1998-05-06 1999-11-16 Yoshio Inoue 胃にやさしい家畜用ミネラル（亜鉛）製剤及びその製造法
US6462075B1 (en) 1999-12-23 2002-10-08 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogensis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
US8168657B2 (en) 2002-01-25 2012-05-01 Bowen J Phillip Solenopsin A, B and analogs and as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (ko) 2003-07-10 2005-07-01 주식회사 바이오리더스 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물
JP4457641B2 (ja) 2003-11-10 2010-04-28 味の素株式会社 ゼラチンカプセル
JP5162812B2 (ja) 2004-07-08 2013-03-13 大正製薬株式会社 亜鉛含有経口投与用組成物
NZ563686A (en) 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
JPWO2007043606A1 (ja) * 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤
US7528125B2 (en) 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
CN101674852A (zh) 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CN101707869A (zh) 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
WO2008140781A1 (en) 2007-05-09 2008-11-20 Atherogenics, Inc. Spiro compounds for treatment of inflammatory disorders
AU2009344184B2 (en) 2009-04-10 2016-05-12 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN101716180B (zh) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 一种组合补充锌、钙药物及其制备方法
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
WO2014081563A1 (en) 2012-11-21 2014-05-30 KBS Research, LLC Herbal supplements and methods of use thereof
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
EP2978423A4 (en) * 2013-03-28 2016-08-24 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
CN112023054A (zh) 2013-04-12 2020-12-04 内德生物系统有限公司 癌症的治疗
CN105143242A (zh) 2013-04-26 2015-12-09 日东电工株式会社 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法
WO2015009699A1 (en) 2013-07-15 2015-01-22 Ketter Patrick Methods and compositions to prevent or treat bacterial infections
JP2016069303A (ja) 2014-09-29 2016-05-09 タカラバイオ株式会社 フコイダンを有効成分とする脱毛抑制用組成物
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
MX2017004473A (es) 2014-10-08 2017-10-12 Synthetic Biologics Inc Formulaciones de betalactamasa y usos de las mismas.
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
WO2016088816A1 (ja) 2014-12-03 2016-06-09 ノーベルファーマ株式会社 酢酸亜鉛水和物錠及びその製造方法
AU2017312121A1 (en) 2016-08-19 2019-03-21 Brooklyn Immunotherapeutics Llc Uses of PD-1/PD-L1 inhibitors and/or CTLA-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
WO2019245458A1 (en) 2018-06-22 2019-12-26 Xylonix Ip Holdings Pte. Ltd. Oncology treatments using zinc agents

Also Published As

Publication number Publication date
AU2023203220B2 (en) 2025-07-31
US20190255104A1 (en) 2019-08-22
AU2017354787B2 (en) 2023-02-23
SG11201903753QA (en) 2019-05-30
EP3534914B1 (en) 2025-07-16
KR102616690B1 (ko) 2023-12-21
SG10202013112YA (en) 2021-02-25
AU2017354787A1 (en) 2019-05-16
EP3534914A1 (en) 2019-09-11
KR20190120159A (ko) 2019-10-23
WO2018084806A1 (en) 2018-05-11
CN116350658A (zh) 2023-06-30
MX395613B (es) 2025-03-25
AU2023203220A1 (en) 2023-06-22
JP2022116255A (ja) 2022-08-09
MX2019005104A (es) 2019-10-30
US20250025496A1 (en) 2025-01-23
CN108014131A (zh) 2018-05-11
EP3534914C0 (en) 2025-07-16
US11944640B2 (en) 2024-04-02
CN108014131B (zh) 2023-04-14
JP2019534330A (ja) 2019-11-28
JP7083835B2 (ja) 2022-06-13
JP7466822B2 (ja) 2024-04-15
SG10201609131YA (en) 2018-06-28
CA3042383A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12014501560A1 (en) Carbamate compounds and of making and using same
NZ700759A (en) Combination therapy for treating cancer
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
IN2015DN00376A (es)
MX2016007351A (es) Terapia de combinacion para tratar cancer.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12020500666A1 (en) Pladienolide compounds and their use
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist